Navigation Links
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/30/2009

onal disease who received Stimuvax had a median survival of 30.6 months compared with 13.3 months for similar patients who did not receive the vaccine, a difference of 17.3 months. Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt, Germany, which assumed responsibility for the clinical development of Stimuvax in 2007."

Merck KGaA is conducting a global Phase 3 trial of Stimuvax known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy.

PX-866

Preliminary results of Oncothyreon's ongoing Phase 1 trial of PX-866, an inhibitor of PI-3 kinase, were presented by Dr. Antonio Jimenez, University of Colorado Cancer Center, Aurora, Colorado. Twenty-six patients have been treated in this trial at once daily doses ranging from 0.5 mg to 10 mg. The maximally tolerated dose has not yet been identified. The most common treatment-related adverse events at the doses tested include low-grade nausea, vomiting and diarrhea. Of 24 evaluable patients, six patients with previously progressive disease have had stable disease as their best response. Three of these patients remain on therapy. Pharmacodynamic monitoring has demonstrated inhibition of PI-3 kinase activity at doses as low as 1 mg per patient.

"We are excited to have seen stabilization of disease in previously progressing patients, as well as clearcut inhibition of PI-3 kinase activity, even in the early cohorts in this dose escalation trial," said Dr. Kirkman. "We believe these findings may reflect the fact that PX-866 is an irreversible inhibitor of PI-3 kinase, which distinguishes it from other PI-3 kinase inhibitors currently in clinical development."

PX-12

'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... (PRWEB) November 23, 2014 One of the ... of optics and photonics is now available to high school ... low cost. SPIE, the international society for optics and ... the complete SPIE Digital Library available to high ... , “Light-based technologies are integral to all areas of life ...
(Date:11/24/2014)... Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. ... both in the United States District Court for ... . On November 21, 2014 ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 During his ... understood the need to surround himself with great people ... and entrepreneur, his friends often marveled at his extraordinarily ... lived his life and -- even with his death ... the Alzheimer’s disease that would ultimately take his life. ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed ... Technologies Summit in San Francisco to take first place ... Silicon Valley investors and technology elites as the premier ... positions Briteseed to move on to the final ... compete with other elite innovation finalists for a $125,000 ...
Breaking Biology Technology:SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... Research & Development Team, CLINTON, N.J., ... fully,integrated critical care biotherapeutics company, announced that ... President of Translational,Medicine, reporting to Ralf Rosskamp, ... of Ikaria., As Vice President of ...
... Thursday, June 26th at 2:30pm ET, NEW YORK, ... today announced that Michael S. Weiss, the Company,s,Chairman and ... & Co. Healthcare Conference being held in New York ... on Thursday, June 26th at,2:30pm ET and will be ...
... New Generation Biofuels,Holdings, Inc. (AMEX: GNB ), a ... Exchange (AMEX) in mid-April, will join the Russell,Microcap Index ... Friday, June 27th, after the market closes, according to ... ., Membership in the Russell Microcap Index, which ...
Cached Biology Technology:Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine 2Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine 3Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference 2New Generation Biofuels Set to Join Russell Microcap Index 2New Generation Biofuels Set to Join Russell Microcap Index 3
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
(Date:11/2/2014)... put a flashlight up to our palms to see ... St. Louis engineers are using a similar idea to ... of cancerous tissues and to develop potential treatments. ... Professor of Biomedical Engineering at the School of Engineering ... that allows researchers to better focus light in tissue, ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... 2008) Argonne National Laboratory has signed a ... Laboratory (SRNL) to collaborate on nuclear energy and ... U.S. Energy Department (DOE) needs and other important ... remain a leader in nuclear energy research," Argonne ...
... the molecule hydroxyl on another planet for the first ... to unlock the workings of Venuss dense atmosphere. ... of a hydrogen and oxygen atom each. It has ... atmosphere, some 100 km above the surface, by Venus ...
... tea may be able to stave off the cognitive ... to a new study published in the second issue ... of Respiratory and Critical Care Medicine. Researchers examined ... water, on rats who were intermittently deprived of oxygen ...
Cached Biology News:Argonne-SRNL agreement supports critical DOE, national priorities 2Key molecule discovered in Venus's atmosphere 2Green tea compounds beat OSA-related brain deficits 2
...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... Activation of ICE-family proteases/caspases initiates apoptosis in ... Apoptosis Detection Kit provides a simple and ... by flow cytometry in intact cells. ... two aspartate residues linked to rhodamine 110 ...
Biology Products: